While at the University of Toronto, we saw early on how machine learning and convolutional neural networks could be applied for image recognition. We founded Atomwise after we proved the concept that the same technology could be applied to drug discovery by performing computational screens to find molecules worth testing in the lab.
Building on this early success we've expanded the robustness of our models through early collaborations with our academic (AIMS program) and biopharma partnerships. Our technology now scales to screening billions of molecules for multiple projects simultaneously. We now use AI as a robust engine for drug discovery resulting in jointly held assets and our wholly owned pipeline to address previously undrugged diseases.
Invented the first application of CNN technology for drug discovery.
Matured the AtomNet® technology platform by tackling more challenging targets with biopharma and AIMS academic partners.
Massively scaled the AtomNet® platform and grew the company to become the leading AI drug discovery engine in biopharma.
Leveraging our drug discovery engine to deliver better medicines faster.
